Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Annexon, Inc. ANNX

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
12.31
Total sells
0.31
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy 1 2 3 — — 1 1 2 — — — —
Sell — — — — 5 5 — — — — — —
Insider Ownership
17.93%

Capital & Financial Ratios

Market Cap
790.55
Revenue
—
Net Income
(202.67)
Free Cash Flow
(193.23)
Net Debt
(209.24)
Current Ratio
5.53
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.00
P/B ratio
4.57
Past 5Y EPS Growth
(0.09%)
This Y EPS Growth
21.71%
Next Y EPS Growth
5.29%
Next 5Y EPS Growth
43.63%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 259.72 312.02 238.35 209.24
Receivables — — — —
Inventory — — — —
Other — — — —
263.86 316.46 242.19 212.76
2023 2024 2025 Q'26
Payables 5.49 10.43 14.93 15.73
ST’ Debt — — — —
Other 0.04 — — —
17.93 30.51 42.63 38.48
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Year
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (46.80) (48.01) — —
—
’25 (50.05) (38.07) (52.30) (45.93)
(186.36)
’24 (28.27) (21.71) (32.01) (36.01)
(118.01)
’23 (32.99) (36.38) (28.29) (23.48)
(121.14)
’22 (30.29) (28.16) (30.72) (27.14)
(116.31)
’21 (23.44) (24.63) (29.71) (28.32)
(106.11)
’20 (10.00) (10.25) (13.58) (19.26)
(53.09)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (46.80) (48.14) — —
—
’25 (50.13) (38.09) (52.35) (45.93)
(186.49)
’24 (28.27) (21.71) (32.02) (36.02)
(118.02)
’23 (33.13) (36.41) (28.31) (23.48)
(121.33)
’22 (35.50) (29.02) (30.89) (27.42)
(122.83)
’21 (23.47) (24.63) (30.48) (29.18)
(107.76)
’20 (10.00) (10.26) (13.86) (19.43)
(53.55)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.23) (0.28) — —
—
’25 (0.37) (0.34) (0.37) (0.28)
(1.34)
’24 (0.21) (0.23) (0.25) (0.33)
(1.01)
’23 (0.52) (0.47) (0.43) (0.36)
(1.77)
’22 (0.92) (0.96) (0.51) (0.48)
(2.60)
’21 (0.68) (0.82) (0.93) (0.97)
(3.40)
’20 (0.33) (28.87) (0.77) (0.61)
(4.15)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1.4
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.06 1.57 3.86 1.29 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 11.95 7.65 8.40 5.66 — — —
High Price
— — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 80 71 100 96 — — —
Employees
— — — ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 — — —
Revenue/Emp
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% — — — — — —
Gross Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (141.95) (134.24) (138.20) (206.69) ‡‡‡‡‡ — —
EBT
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (141.95) (134.24) (138.20) (206.69) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.11 2.15 2.15 2.17 — — —
Depreciation
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ (2.60) (1.77) (1.01) (1.34) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.13) (1.60) (0.86) (1.20) ‡‡‡‡‡ — —
Cash Flow/Sh
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.12) 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.25) (1.60) (0.86) (1.20) — — —
Free CF/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.23 3.31 2.13 1.36 ‡‡‡‡‡ — —
Book Value/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 54.67 75.67 137.40 155.11 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — — — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — — — — — — — — — — — —
EV/FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (116.31) (121.14) (118.01) (186.36) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.53) (0.19) (0.01) (0.14) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (122.83) (121.33) (118.02) (186.49) ‡‡‡‡‡ — —
FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 225.74 245.93 285.95 199.56 — — —
Working Cap'
— ‡‡‡‡‡ ‡‡‡‡‡ — — ‡‡‡‡‡ 32.86 — — — — — —
Total Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (209.80) (259.72) (312.02) (238.34) — — —
Net Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 231.19 250.56 293.11 211.65 — — —
Sh' Equity
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (49.62%) (46.07%) (42.67%) (66.45%) ‡‡‡‡‡ — —
ROA
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (425.33%) 0.00% 0.00% 0.00% — — —
ROIC
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (61.30%) (55.73%) (50.84%) (82.63%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Annexon, Inc. (ANNX), a clinical-stage biotech targeting neuroinflammatory diseases like Guillain-Barré syndrome and Alzheimer’s, has endured classic pre-revenue volatility: massive losses peaking at -$141.9 million in 2022, zero revenue through 2024, and a stock that plunged 96% from 2021 highs to 2023 lows amid trial setbacks. Yet, a 2024 rebound—up 146% from yearly lows—coincides with a fortified balance sheet boasting $312 million in net cash, stabilizing losses per share, and aggressive employee growth signaling pipeline acceleration.

Insider confidence is surging, with directors snapping up over $8.9 million in shares in late 2024 and early 2025—virtually no sells—aligning with analysts’ rosy projections: revenue exploding from $1 million in 2025 to $52 million by 2027, EPS improving 42% to -$0.81, and mean price targets implying 186% upside (high end 452%). This setups a potential turnaround if Phase 3 trials and approvals deliver.

Risks loom large—dilution from 7x share growth, ~$118 million annual burn limiting runway to 2.5 years, and biotech’s low hit rates—but the convergence of insider buys, data wins, and revenue inflection paints a high-conviction lottery ticket for volatility-tolerant investors. Dive deeper for the full data correlations and catalysts.

Read full commentary →

Annexon, Inc. (ANNX) Latest News

News by impact score

Fine-tune

24 Aug

4 , 4:08 AM
Annexon updates ARCHER II trial with dual endpoints, indicating clinical progress that could alter development plans and shareholder value. Dual-endpoint ARCHER II update marks major clinical milestone likely to shift Annexon's trajectory and investor outlook.

19 Aug

3 transcript www.fool.com, 9:58 AM
Annexon (ANNX) released its Q2 2026 earnings call transcript covering financial results and outlook. Quarterly earnings updates typically influence near-term sentiment and valuation without major structural shifts.

13 Aug

3 , 2:13 PM
Annexon provided an update on its complement-targeted therapies, highlighting progress in clinical programs for geographic atrophy and other indications with new data readouts and pipeline advancements. Pipeline updates and clinical data releases may moderately affect near-term sentiment and valuation but lack immediate regulatory or commercial outcomes.

12 Aug

4 , 6:05 AM
Annexon, Inc. reported second quarter 2026 financial results along with business updates and key anticipated milestones. Quarterly financial results combined with milestone updates typically drive material shifts in valuation and investor outlook for clinical-stage biotech firms.

4 , 6:00 AM
Annexon expands Vonaprument Phase 3 program in Geographic Atrophy by adding Month 24 dual primary endpoint to complement Month 15 primary endpoint and launches open-label extension study. Phase 3 program expansion with added endpoints and extension study advances Vonaprument toward potential approval and strengthens Annexon positioning in geographic atrophy.

3 transcript app.moby.co, 4:56 PM
Annexon, Inc. held its Q2 2026 earnings call covering quarterly financial results and business updates. Quarterly earnings data typically influences near-term stock valuation and investor views without major strategic shifts.

3 www.marketbeat.com, 9:03 AM
Annexon Q2 earnings call highlights include financial results, pipeline progress and operational updates for the biotech company. Routine quarterly earnings updates can shift near-term sentiment and trading but rarely alter long-term company trajectory.

6 Aug

4 , 8:00 AM
Annexon reports rapid positive clinical responses within one week in all tanruprubart-treated patients from the first U.S. and European cohort of the GBS FORWARD study. Positive early GBS study data for tanruprubart signals major upside for regulatory progress and commercial potential.

30 Jul

4 , 4:01 PM
Annexon secures strategic credit facility for up to $200 million from Oxford Finance. Up to $200 million credit facility materially extends Annexon's financial runway and supports ongoing pipeline development.

16 Jul

4 , 7:17 PM
Annexon achieved a Phase 3 win for Tanruprubart and released Vonaprument updates, driving investor reactions to the clinical progress. Phase 3 success for Tanruprubart signals major regulatory and commercial potential that can shift Annexon's trajectory.

9 Jun

4 www.marketbeat.com, 9:06 AM
Annexon anticipates positive Q4 vision trial data and plans GBS regulatory filings, targeting a period of strong results. Vision trial readout and GBS filings are pivotal milestones that can drive major shifts in company valuation.

4 Jun

4 www.marketbeat.com, 3:07 AM
Annexon maps three major pipeline catalysts ahead of its Q4 vision-drug readout. Pipeline catalysts and clinical readouts frequently drive major shifts in biotech valuation and trajectory.

14 May

4 www.marketbeat.com, 4:05 AM
Annexon, Inc. highlighted Q4 geographic atrophy data and outlined GBS filing plans during the Bank of America conference. Pipeline progress with positive data readout and upcoming regulatory filing plans could significantly boost ANNX's clinical trajectory and investor sentiment.

7 May

4 GlobeNewswire, 4:01 PM
Annexon, Inc. (ANNX) reported first quarter 2026 financial results, portfolio progress, and key anticipated milestones. Quarterly financial results with portfolio advancements and upcoming milestones represent significant strategic updates likely to impact ANNX trajectory and investor sentiment.

15 Apr

4 www.marketbeat.com, 5:02 PM
Annexon CEO predicts 2026 as a 'win year' at Needham conference, highlighting upcoming Phase III data readout for geographic atrophy and FDA filing for Guillain-Barré syndrome. CEO's focus on Phase III data and FDA filing signals major pipeline milestones poised to drive significant investor sentiment and valuation shifts.

1 Apr

3 Simply Wall St., 6:59 AM
Annexon (ANNX) undergoes assessment of its readiness to execute growth plans, highlighting strong cash position, advancing clinical pipeline in neuroinflammation, positive Phase 3 data for ANX005 in Guillain-Barré Syndrome, and strategic priorities amid biotech challenges. Assessment of financial runway, pipeline progress, and growth strategy provides moderate insight into operational momentum and investor confidence.

30 Mar

4 GlobeNewswire, 4:01 PM
Annexon, Inc. (ANNX) reported fourth quarter and year-end 2025 financial results, portfolio progress, and key anticipated milestones. Financial results, portfolio advancements, and upcoming milestones significantly shape ANNX's trajectory and investor sentiment.

18 Mar

4 www.marketbeat.com, 10:02 PM
Annexon Investor Day highlights ANX007 targeting C1q in dry AMD geographic atrophy, with Phase III readout nearing Q4. Imminent Phase III readout for ANX007 in dry AMD GA represents a major pipeline catalyst with potential to drive significant stock movement and strategic value.

4 Mar

4 www.marketbeat.com, 5:48 AM
Annexon, Inc. highlighted its geographic atrophy Phase III trial progress, Guillain-Barré syndrome regulatory plans, and ANX1502 development update during a presentation at the TD Cowen Conference. Advancing Phase III trial for GA and outlining GBS regulatory path alongside ANX1502 updates represent major pipeline milestones that could drive significant stock momentum and reshape competitive positioning.

17 Feb

4 GlobeNewswire, 8:00 AM
Annexon, Inc. (ANNX) to host in-person and virtual KOL event discussing vonaprument for geographic atrophy treatment. KOL event highlights vonaprument progress in competitive geographic atrophy market, likely boosting investor sentiment and stock trajectory.

20 Jan

4 Simply Wall St., 10:10 AM
Annexon, Inc. has filed for European Medicines Agency (EMA) approval for its drug Tanruprubart, aimed at treating patients with autoimmune diseases. This filing is seen as a pivotal moment for the company, potentially reshaping the bullish outlook for its stock. Analysts are evaluating the implications of this regulatory move on Annexon's market position and future growth prospects, as successful approval could enhance investor confidence and drive stock performance. The EMA filing for Tanruprubart represents a significant regulatory milestone that could greatly influence Annexon's market trajectory and investor sentiment.

18 Jan

4 Simply Wall St., 10:10 AM
Annexon, Inc. has filed for European Medicines Agency (EMA) approval for tanruprubart, a treatment aimed at Guillain-Barré syndrome. This filing is a significant step for the company as it seeks to expand its product offerings and address unmet medical needs in this area. The potential approval could enhance Annexon's market position and investor interest, depending on the outcome of the regulatory review. The EMA filing for tanruprubart represents a major strategic move that could significantly alter Annexon's trajectory and investor sentiment.

14 Jan

4 www.marketbeat.com, 5:10 PM
Annexon, Inc. outlined its strategic plans for 2026 during the JPM Conference, highlighting the upcoming Phase 3 readout for ANX007 targeting geographic atrophy (GA) and the anticipated regulatory filings for ANX005. These developments are positioned as pivotal for the company's future trajectory. The Phase 3 readout and regulatory filings are significant strategic moves that could greatly influence Annexon's market position and investor sentiment.

12 Jan

4 GlobeNewswire, 7:00 AM
Annexon, Inc. is advancing its next-generation targeted immunotherapy platform aimed at treating neuroinflammatory diseases, with multiple registrational milestones anticipated in 2026. The company is focusing on innovative therapies that could significantly impact patient care in this area. The upcoming registrational milestones and advancements in targeted immunotherapy are likely to significantly influence Annexon's market position and investor sentiment.

8 Jan

4 GlobeNewswire, 8:00 AM
Annexon, Inc. has submitted a Marketing Authorization Application for its drug Tanruprubart to the European Medicines Agency, targeting Guillain-Barré Syndrome. This submission is a significant step in the regulatory process, aiming to provide a new treatment option for patients suffering from this rare neurological disorder. The submission of the Marketing Authorization Application represents a major strategic move that could significantly alter the company's trajectory and investor sentiment.

18 Dec

4 Insider Monkey, 1:14 AM
Clear Street has reaffirmed a buy rating on Annexon, Inc. (ANNX) as the company makes notable progress in its pipeline development. This endorsement reflects confidence in Annexon's potential to advance its therapeutic candidates and enhance its market position. Progress on pipeline development is likely to significantly impact Annexon's future performance and investor sentiment.

15 Dec

4 Simply Wall St., 6:38 AM
Annexon, Inc. (ANNX) is highlighted as one of three high-growth tech stocks to watch in the U.S. market. The company focuses on developing innovative therapies for neurodegenerative diseases, leveraging its unique approach to target the complement system. With promising clinical trials and a strong pipeline, Annexon is positioned for significant growth in the biotech sector, attracting investor interest amid a competitive landscape. Promising clinical trials and a strong pipeline could significantly alter the company's trajectory and investor sentiment.

11 Dec

3 Simply Wall St., 12:52 PM
Annexon, Inc. (ANNX) shares surged by 14%, prompting insider buyers to reflect on their profitable investments. The increase in stock price has generated positive sentiment among investors, particularly those who purchased shares recently. This uptick may indicate growing confidence in the company's future prospects and market position. The stock price increase suggests a moderately noticeable influence on investor sentiment and potential future performance.

29 Nov

4 Insider MonkeyMT NewswiresMT NewswiresInsider Monkey, 1:26 AM
Analysts express strong confidence in Annexon, Inc. (ANNX) as the company advances its lead product, vonaprument, which targets neurodegenerative diseases. Positive clinical trial results and strategic partnerships are bolstering investor sentiment and expectations for future growth. The advancements in vonaprument are seen as pivotal for the company's market position and potential revenue generation. Advancements in vonaprument are likely to significantly impact Annexon's future performance and investor sentiment.

14 Nov

4 GlobeNewswire, 4:01 PM
Annexon, Inc. has successfully closed its public offering, raising gross proceeds of $86.25 million following the full exercise of underwriters’ option to purchase additional shares. This capital infusion is expected to support the company's ongoing development and operational initiatives. The successful capital raise is a significant strategic move that could enhance Annexon's financial position and support future growth initiatives.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us